Technical Analysis for KALA - Kala Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Historical KALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| 20 DMA Resistance | Bearish | -0.46% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -0.46% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.46% | |
| Narrow Range Bar | Range Contraction | -0.46% | |
| 20 DMA Resistance | Bearish | -1.37% | |
| Boomer Buy Setup | Bullish Swing Setup | -1.37% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/12/2020
- Sector: Healthcare
- Industry: Biotechnology
Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Medicine Medical Specialties Pain Organ Systems Macular Degeneration Wet Age Related Macular Degeneration Glucocorticoids Post Surgical Ocular Inflammation Retinal Disease
Medicine Medical Specialties Pain Organ Systems Macular Degeneration Wet Age Related Macular Degeneration Glucocorticoids Post Surgical Ocular Inflammation Retinal Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.98 |
| 52 Week Low | 3.24 |
| Average Volume | 750,525 |
| 200-Day Moving Average | 4.92 |
| 50-Day Moving Average | 5.47 |
| 20-Day Moving Average | 6.58 |
| 10-Day Moving Average | 6.51 |
| Average True Range | 0.51 |
| ADX | 32.35 |
| +DI | 22.66 |
| -DI | 18.54 |
| Chandelier Exit (Long, 3 ATRs ) | 6.17 |
| Chandelier Exit (Short, 3 ATRs ) | 7.24 |
| Upper Bollinger Band | 7.24 |
| Lower Bollinger Band | 5.92 |
| Percent B (%b) | 0.44 |
| BandWidth | 20.11 |
| MACD Line | 0.26 |
| MACD Signal Line | 0.34 |
| MACD Histogram | -0.0843 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.07 | ||||
| Resistance 3 (R3) | 7.04 | 6.81 | 6.98 | ||
| Resistance 2 (R2) | 6.81 | 6.67 | 6.83 | 6.94 | |
| Resistance 1 (R1) | 6.66 | 6.58 | 6.55 | 6.69 | 6.91 |
| Pivot Point | 6.43 | 6.43 | 6.38 | 6.45 | 6.43 |
| Support 1 (S1) | 6.28 | 6.29 | 6.17 | 6.31 | 6.09 |
| Support 2 (S2) | 6.05 | 6.20 | 6.07 | 6.06 | |
| Support 3 (S3) | 5.90 | 6.05 | 6.03 | ||
| Support 4 (S4) | 5.93 |
